NCT07210034Not yet recruiting
What is the Prognostic Value of HALP Score, Monocytopenia, Hypofibrinogenemia, and AST/ALT Ratio in Patients With Myelodysplastic Syndromes
Prognostic Value of HALP Score, Monocytopenia, Hypofibrinogenemia, and AST/ALT Ratio in Patients With Myelodysplastic Syndromes at Assiut University Hospital.
Source: ClinicalTrials.gov · Last updated 7 Oct 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
to investigate prognostic significance of many factors in MDS including HALP score ( haemoglobin level, albumin level, lymphocyte, platelets), monocytopenia, hyperfibrinogenemia and AST/ALT ratio in patients with MDS at Assiut University Hospital. And to study overall survival and leukemia free survival rates in MDS patients.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 100 (estimated)
- First submitted
- 29 Sept 2025
- Start date
- 1 Jan 2026
- Primary completion date
- 1 Jan 2028
- Lead sponsor
- Assiut University
- Diseases
- Myelodysplastic syndromes
- NCT number
- NCT07210034
What you commit to
- Study type: Observational
- Planned participants: 100
- From 1 Jan 2026 to the primary completion date, 1 Jan 2028
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients with active infections, liver cirrhosis, chronic inflammatory diseases, or concurrent malignancies at time of diagnosis
Lab values
- Incomplete laboratory or clinical data
Other
- Patients lost to follow-up within less than 3 months of diagnosis
Who the study is looking for
- • Adults (≥18 years old) diagnosed with MDS according to WHO criteria
- Availability of complete medical records including laboratory data for hemoglobin, albumin, lymphocyte count, platelet count, monocyte count, fibrinogen level, AST and ALT
- Patients who were followed for at least 12 months post-diagnosis or until death
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.